Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Long-Lasting Results with Hydroxylapatite (Radiesse) Facial Filler

Jacovella, Patricio F. M.D.; Peiretti, Claudia B. M.D.; Cunille, Diego M.D.; Salzamendi, Mauricio M.D.; Schechtel, Sophia Asiu M.D.

Plastic and Reconstructive Surgery: September 1, 2006 - Volume 118 - Issue 3S - p 15S-21S
doi: 10.1097/01.prs.0000234902.61284.c9
COSMETIC: ORIGINAL ARTICLES
Buy

Background: This study examined the patient satisfaction and longevity of Radiesse, a calcium hydroxylapatite compound, as a facial soft-tissue filler for the glabellar lines, the lips, the nose, the face, and the infraorbital region.

Methods: Radiesse, 0.5 to 2.0 ml, was injected into the designated area in each of the 40 Argentinian male and female patients in the study, using a fine needle. The age range of the patients was 25 to 60 years.

Results: Patients were observed over a period of 18 months. No systemic effects, no immunologic responses, and minimal adverse events (ecchymosis and hematoma in 5 percent of the subjects) occurred with the treatment. In the patient satisfaction survey, 87 percent of the patients rated their level of satisfaction as acceptable or better.

Conclusions: Radiesse was shown to be a highly effective, long-lasting material for facial soft-tissue augmentation. The safe and well-tolerated compound drew high marks in patient satisfaction. A precise injection technique helped minimize potential effects such as nodule formation and helped avoid persistent overcorrection, livid coloring, and asymmetry. Radiesse can be considered a very good option for an aesthetic soft-tissue facial filler when real volumetric augmentation is needed.

Buenos Aires, Argentina.

From the University of Buenos Aires.

Received for publication February 14, 2005; accepted May 11, 2005.

Presented in part at the at the American Society of Plastic Surgeons 2004 Annual Meeting, in Philadelphia, Pennsylvania, on October 10, 2004.

Patricio F. Jacovella, M.D., Ph.D.; Plastic Surgery Residency; University of Buenos Aires; 1754 Guido Street; 01016 Buenos Aires, Argentina; pjacovella@elsitio.net

The implant compound hydroxylapatite has already received FDA approval for laryngeal augmentation, soft-tissue marking, and filling/augmentation of dental intraosseous defects and oral/maxillofacial defects. It has been used as a transurethral bulking agent for stress urinary incontinence. The use for facial aesthetics is “off-label.”

©2006American Society of Plastic Surgeons